WallStreetZenWallStreetZen

NASDAQ: MBRX
Moleculin Biotech Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Moleculin Biotech earnings were -$32.5M for the trailing 12 months ending Jun 30, 2026, with N/A growth year over year. The latest MBRX earnings report on Jun 30, 2026 announced Q2 2026 earnings of -$8.0M, down 45.5% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, MBRX reported annual earnings of -$33.7M, with 29.2% growth.

MBRX earnings history

Current Revenue
$0.0
Current Earnings
-$32.5M
Current Profit Margin
0%

MBRX Return on Equity

Current Company
-875.7%
Current Industry
-13.6%
Current Market
30.9%
MBRX's Return on Equity (-875.7%)... subscribe to Premium to read more.
High Return on Equity Performance

MBRX Return on Assets

Current Company
-149.7%
Current Industry
-10.3%
MBRX is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when MBRX announces earnings.

MBRX Return on Capital Employed

Current Company
-256.91%
Current Industry
-7%
MBRX's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

MBRX vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
MBRX-$30.20M-$32.53MN/A$8.64
CNSY-$25.63M-$26.09MN/A-$3.36
ICU-$13.60M-$13.63MN/A-$2.97
DYAI-$7.17M-$7.62MN/A-$0.23
LSTA-$14.94M-$14.62MN/A-$1.64
View Top Biotech Stocks

Moleculin Biotech Earnings Reports & History FAQ

What were Moleculin Biotech's earnings last quarter?

On MBRX's earnings call on Aug 11, 2026, Moleculin Biotech (NASDAQ: MBRX) reported Q2 2026 earnings per share (EPS) of -$1.40, up 95.12% year over year. Total MBRX earnings for the quarter were -$7.96 million. In the same quarter last year, Moleculin Biotech's earnings per share (EPS) was -$28.68.

If you're new to stock investing, here's how to buy Moleculin Biotech stock.

Is Moleculin Biotech profitable or losing money?

As of the last Moleculin Biotech earnings report, Moleculin Biotech is currently losing money. Moleculin Biotech's net profit (also called net income) for the twelve months ending Jun 30, 2026 was -$30.33 million, a 18.74% decrease year over year.

What was MBRX's earnings growth in the past year?

As of Moleculin Biotech's earnings date in Aug 11, 2026, Moleculin Biotech's earnings has grown year over year. MBRX earnings in the past year totalled -$32.53 million.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.